Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Theratechnologies Inc. (T:TH)

Business Focus: Specialty & Advanced Pharmaceuticals

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for TH within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Nov 23, 2020 16:01 ET
Theratechnologies to Present at the Piper Sandler Virtual Healthcare Conference
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that some of its management team members will be...
Read full article
Nov 16, 2020 10:30 ET
Theratechnologies Announces Data From Oral Presentation at AASLD Showing How Tesamorelin Can Reduce Fibrosis and NASH
Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today highlighted new data on the mechanism of effect of tesamorelin...
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
1.76
--
--
Price to Sales - TTM
2.81
3.29
9.52
Price to Book - most recent quarter
20.85
0.78
3.16
Price to Cash Flow per share - TTM
--
15.08
11.77
Price to Free Cash Flow per share - TTM
--
--
19.57
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Nov 30, 2020896,815255,418
Nov 15, 2020641,39750,871
Oct 31, 2020590,52653,901
See Short Report

Business Summary

Sector:  Healthcare Industry:  Pharmaceuticals

Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs to promote healthy living for human immunodeficiency virus (HIV) patients. Its products include EGRIFTA and Ibalizumab. EGRIFTA (tesamorelin for injection) refers to tesamorelin and it is indicated for the reduction of excess abdominal fat in HIV infected patients with lipodystrophy. EGRIFTA is indicated for the treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference of approximately 100 centimeters for males and approximately 90 centimeters for females. Ibalizumab is a cluster difference 4 (CD4)-directed HIV entryinhibitor, which focuses on treating multidrug resistant HIV-1 infection (MDR HIV-1). Ibalizumab binds to the second extracellular domain of the CD4 receptor. Ibalizumab has completed the Phase III trial. EGRIFTA is available in Canada and in the United States. The Company distributes EGRIFTA in the United States through RxC Acquisition.

See business summary

 

Twitter

Search (past week) for $TH.CA

  • No tweets found